摘要
Abstract
Objective:To evaluate the therapeutic efficacy of Edaravone Dexborneol combined with Shuxuening in pa-tients with acute cerebral infarction(ACI).Methods:A total of 80 ACI patients admitted to the hospital from Janu-ary 2020 to March 2024 were enrolled and randomly divided into two groups using a random number table.The con-trol group(40 cases)received Edaravone Dexborneol injection,while the observation group(40 cases)received ad-ditional Shuxuening therapy.Clinical outcomes,including neurological function,coagulation parameters,and in-flammatory markers,were compared between the two groups.Results:Post-treatment,the observation group ex-hibited significantly lower National Institutes of Health Stroke Scale(NIHSS)scores compared to the control group,P<0.05.The total effective rate in the observation group(95.24%)was markedly higher than that in the control group(80.95%),P<0.05.Additionally,the observation group demonstrated prolonged prothrombin time(PT),activated partial thromboplastin time(APTT),and thrombin time(TT),along with reduced fibrinogen(FIB),serum homocysteine(Hcy),and C-reactive protein(CRP)levels compared to the control group,P<0.05.Conclusion:The combination of Edaravone Dexborneol and Shuxuening demonstrates reliable efficacy in ACI treatment,improving coagulation function,reducing neurological deficits,and lowering inflammatory markers.关键词
依达拉奉右莰醇/舒血宁/急性脑梗死/血清炎性指标Key words
Edaravone dextroamphetamine/Shuxaunin/Acute cerebral infarction/Serum inflammatory indexes分类
医药卫生
